Olivia Newton-John Cancer Research Institute, Heidelberg, VIC 3084, Australia.
School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.
Int J Mol Sci. 2021 Mar 11;22(6):2841. doi: 10.3390/ijms22062841.
B-Cell Lymphoma 2 (BCL-2), c-MYC and related proteins are arguably amongst the most widely studied in all of biology. Every year there are thousands of papers reporting on different aspects of their biochemistry, cellular and physiological mechanisms and functions. This plethora of literature can be attributed to both proteins playing essential roles in the normal functioning of a cell, and by extension a whole organism, but also due to their central role in disease, most notably, cancer. Many cancers arise due to genetic lesions resulting in deregulation of both proteins, and indeed the development and survival of tumours is often dependent on co-operativity between these protein families. In this review we will discuss the individual roles of both proteins in cancer, describe cancers where co-operativity between them has been well-characterised and finally, some strategies to target these proteins therapeutically.
B 细胞淋巴瘤 2(BCL-2)、c-MYC 及相关蛋白无疑是所有生物学中研究最广泛的蛋白之一。每年都有数千篇论文报道它们在生化、细胞和生理机制及功能方面的不同方面。如此丰富的文献可以归因于这两种蛋白在细胞正常功能中发挥着重要作用,进而在整个生物体中也发挥着重要作用,还归因于它们在疾病(尤其是癌症)中的核心作用。许多癌症是由于遗传损伤导致这两种蛋白的失调而产生的,事实上,肿瘤的发生和存活通常依赖于这两种蛋白家族之间的协同作用。在这篇综述中,我们将讨论这两种蛋白在癌症中的各自作用,描述它们之间协同作用得到充分表征的癌症,最后,我们将讨论一些针对这些蛋白的治疗策略。